Fda provides seven years of orphan-drug exclusive approval for ryoncil®

New york, may 14, 2025 (globe newswire) -- mesoblast (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from u.s. food and drug administration (fda) for ryoncil® (remestemcel-l) for treatment of steroid-refractory acute graft versus host disease (sr-agvhd) in pediatric patients 2 months of age and older.
MESO Ratings Summary
MESO Quant Ranking